Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IDIBELL Licenses to Janus a Patent for the Treatment of Immune Diseases

Published: Thursday, December 06, 2012
Last Updated: Thursday, December 06, 2012
Bookmark and Share
The technology has been developed entirely in the Institute.

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the company Janus Developments of a patent for an immunomodulatory product for treating immune diseases such as autoimmune diseases, sepsis, hypersensitivity disorders (including, allergic reactions) or post-transplant rejection. The patent has been developed by the researcher of the Human Molecular Genetics group Josep Maria Aran and his team.

The invention relates to a concrete form of C4BP protein (C4b-binding protein), which is able to inhibit other proteins in the complement system, a major component of the innate immune response.

Step into the market

Many years will be needed before the product developed by Dr. Aran can be applied in humans. It will require additional preclinical studies and clinical trials in humans. In this sense, the signing of the license agreement is an important step to complete these studies and to become in the future a pharmaceutical product.

The head of the Technology Transfer Office (TTO) at IDIBELL, Montse Ballarín, highlights the fact that "the license products developed at our institution reflects the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market."

Ballarín stresses that the transfer of a technology or a product to industry is not an easy process. "You have to offer a good product that meets a market need, to solve an unsolved problem, a technically and economically feasible production, a will to buy by the health system and a long list of conditions that are overcome before to achieve the interest of the company." Finally, "there is a good bargain to adequately protect the interests of inventors and the institution", explains the OTRI responsible.

Janus Developments is a company dedicated to biomedical knowledge transfer to the market. Currently develop eleven projects based on patents originated at several universities and research centres. In addition, Janus timely collaborates in defining and implementing various companies and foundations. Janus Developments supports IDIBELL in transfer activities, from identifying technologies to the introduction to market.

The license signed with Janus is the first patent that IDIBELL, through its TTO, has been transferred to a company outside the campus (previously had managed licensing contracts with spin-offs arising from the institution). Also recently it has been transferred a diagnostic technology and a patent to a multinational pharmaceutical company. At this time, IDIBELL is on track to close two licensing agreements over two patents developed by researchers at the centre.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Keeping Growth in Check
Ribosomal proteins RPL5 and RPL11 play an essential role in normal cell proliferation.
Friday, December 13, 2013
Key Role of a Protein in the Segregation of Genetic Material During Cell Division
Researchers at IDIBELL have reported an article which delves into the regulator mechanisms of mitosis.
Wednesday, December 11, 2013
Discovered a Mechanism that Induces Migration of Tumor Cells in Liver Cancer
Coordinated overactivation of TGFb and CXCR4 signaling pathways confer migratory properties to the hepatocellular carcinoma cells.
Wednesday, November 06, 2013
The European Union Allocates Six Million Euros to Study Prevention Strategies Tumors Caused by HPV
The human papillomavirus (HPV) is responsible for cervical cancer and is behind a significant percentage of other tumors such as vulva , vagina, penis, anus, and oropharynx.
Tuesday, November 05, 2013
Researchers Discover the Genetic Signature of Highly Aggressive Small Lung Tumors
A study conducted by the IDIBELL allows to identify this type of cancer at an early stage and adapt the treatment.
Thursday, October 03, 2013
Discovered Epigenetic Alterations in the Brain of Alzheimer's Patients
Alzheimer disease is becoming a major health problem in Western societies, exacerbated by the progressive aging of the population.
Monday, September 16, 2013
High Levels of RANK Protein Interferes with the Differentiation of Mammary Cells
Levels of this protein increase with age, which could explain the increase in breast cancer risk associated with age.
Wednesday, September 11, 2013
The Epigenome Differentiates the Different Human Populations
Establishing what differentiates us from our neighbors, our friends or strangers from distant countries.
Monday, August 05, 2013
Patented, a Molecule that Opens the Door to Develop New Drugs Against Immune Rejection
Researchers have patented a peptide that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs.
Thursday, August 01, 2013
Discovered a Future Therapeutic Target for Lung Cancer Treatment
One of the goals of research in cancer genetics and molecular biology is to get an "on demand" treatment, with maximum effect and minimal toxicity.
Monday, July 22, 2013
Brain Epigenome Changes from Birth to Adolescence
Experience of parents with their children and teachers with their students demonstrate how kids change their behaviours and knowledge from childhood to adolescence.
Friday, July 05, 2013
Discovered the Role of Noncoding 5S rRNA in Protecting the p53 Tumor Suppressor Gene
Over 50% of tumors are associated with mutations in p53.
Thursday, July 04, 2013
A Gene Conserved from Worms to Humans Opens the Door to new Therapeutics
Gene shows promising therapeutic strategies in cancer and in some types of blindness.
Friday, June 21, 2013
Genetically Modified Stem Cells are Effective Against Acute Respiratory Diseases
Administration of genetically modified mesenchymal stem cells regenerates lung tissue and stops the inflammatory process in mice with acute lung injury.
Tuesday, June 18, 2013
An Epigenetic Change Causes the Block of Antitumor Genes
Healthy cells live in a delicate balance between growth-promoting genes (oncogenes) and those who restrain it (anti-oncogenes or tumor suppressor genes).
Wednesday, June 12, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!